{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Efatutazone",
  "nciThesaurus": {
    "casRegistry": "223132-37-4",
    "chebiId": "",
    "chemicalFormula": "C27H26N4O4S",
    "definition": "An orally bioavailable thiazolidinedione and an agonist of peroxisome proliferator-activated receptor gamma (PPAR-gamma) with potential antineoplastic activity. Efatutazone binds to and activates PPAR-gamma thus inducing cell differentiation and apoptosis, leading to a reduction in cellular proliferation. PPAR-gamma is a nuclear hormone receptor and a ligand-activated transcription factor that controls the expression of genes involved in macromolecule metabolism and cell differentiation, specifically adipocyte differentiation.",
    "fdaUniiCode": "M17ILL71MC",
    "identifier": "C83819",
    "preferredName": "Efatutazone",
    "semanticType": "Pharmacologic Substance",
    "subclassOf": [
      "C1934"
    ],
    "synonyms": [
      "2,4-Thiazolidinedione, 5-((4-((6-(4-Amino-3,5-Dimethylphenoxy)-1-Methyl-1H-Benzimidazol-2-yl)Methoxy)Phenyl)Methyl)-",
      "EFATUTAZONE",
      "Efatutazone",
      "Inolitazone",
      "Rac-5-((4-((6-(4-Amino-3,5-Dimethylphenoxy)-1-Methyl-1H-Benzimidazol-2-yl)Methoxy)Phenyl)Methyl)-1,3-Thiazolidine-2,4-Dione"
    ]
  }
}